Last reviewed · How we verify
SEN0014196
At a glance
| Generic name | SEN0014196 |
|---|---|
| Sponsor | Siena Biotech S.p.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SIRT-1 Antagonism for Endometrial Receptivity (PHASE2)
- A Phase II Safety and Tolerability Study With SEN0014196 (PHASE2)
- An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 (PHASE1)
- A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease (PHASE1)
- Escalating Dose Study in Healthy Volunteers With SEN0014196 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEN0014196 CI brief — competitive landscape report
- SEN0014196 updates RSS · CI watch RSS
- Siena Biotech S.p.A. portfolio CI